-
Mashup Score: 137
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Chernobyl and Biology: Dual Degree Prompts Alumni Award Winner to Pivot | School of Molecular & Cellular Biology | UIUC - 9 day(s) ago
Congratulations to Dr. Mesa, a 2024 College of Liberal Arts & Sciences Distinguished Alumni Award Recipient!
Source: mcb.illinois.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Navigating Emerging Therapies in Myelofibrosis Treatment - 13 day(s) ago
In an interview, Raajit K. Rampal, MD, PhD, delved into the dynamic landscape of myelofibrosis therapy, highlighting treatment options beyond JAK inhibition.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Gut Microbiota Differs in Patients With MPNs - 16 day(s) ago
Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 41
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS - 20 day(s) ago
Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The unique ability of imetelstat to significantly reduce transfusion dependence and potential to modify disease in patients with lower-risk MDS who cannot receive standard ESAs may lead to improved QOL in this setting. @Sunil_G_Iyer @columbiacancer #mpnsm https://t.co/55e6j64o7T https://t.co/fMqMOmC3GE
-
-
Mashup Score: 7Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS - 22 day(s) ago
Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The unique ability of imetelstat to significantly reduce transfusion dependence and potential to modify disease in patients with lower-risk MDS who cannot receive standard ESAs may lead to improved QOL in this setting. @Sunil_G_Iyer @columbiacancer #mpnsm https://t.co/55e6j64o7T https://t.co/fMqMOmC3GE
-
-
Mashup Score: 1
An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Navigating Emerging Therapies in Myelofibrosis Treatment - 1 month(s) ago
In an interview, Raajit K. Rampal, MD, PhD, delved into the dynamic landscape of myelofibrosis therapy, highlighting treatment options beyond JAK inhibition.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management |American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/fAWl1X6Ra8 #mpnsm https://t.co/GZNuZwfzTX